• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma

by MM360 Staff | Aug 5, 2025 | Myeloma News

Source: Pharmacy Times articles Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission. Read More

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma

by MM360 Staff | Aug 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Video: Pharmacists Take Center Stage in Delivering Linvoseltamab, Advancing Myeloma Care

by MM360 Staff | Aug 2, 2025 | Myeloma News

Source: Pharmacy Times articles Sundar Jagannath, MBBS, highlights pharmacists’ expanding role in managing linvoseltamab’s immunologic profile, supporting adverse event response, and advancing multiple myeloma care. Read More

SAR446523 Granted Orphan Drug Designation for Patients With Relapsed, Refractory Multiple Myeloma

by MM360 Staff | Aug 1, 2025 | Myeloma News

Source: Pharmacy Times articles Sanofi’s SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes. Read More

Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT

by MM360 Staff | Jul 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement

by MM360 Staff | Jul 31, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries

Recent Content

  • Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma
  • Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma
  • Video: Pharmacists Take Center Stage in Delivering Linvoseltamab, Advancing Myeloma Care
  • SAR446523 Granted Orphan Drug Designation for Patients With Relapsed, Refractory Multiple Myeloma
  • FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma
  • Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT
  • Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
  • Expert: Linvoseltamab’s Simplified Dosing Expands Access, Enhances Tolerability in Multiple Myeloma
  • Patient Perspective: Navigating Multiple Myeloma Treatment
  • LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT